Compare Atmos Energy Corporation (ATO) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Atmos Energy Corporation vs Incyte Corporation — how do they compare? Atmos Energy Corporation trades at $177.65 (market cap $29.79B), while Incyte Corporation trades at $114.6 (market cap $22.95B). The key difference: Atmos Energy Corporation is the larger of the two by market cap, and Atmos Energy Corporation pays a 2.24% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| ATO | INCY | |
|---|---|---|
Market Cap | $29.79B | $22.95B |
Sector | Utilities | Health |
52-Week High | $192.25 | $118.52 |
52-Week Low | $154.10 | $67.38 |
Enterprise Value | $39.29B | $18.97B |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Atmos Energy (ATO) trades at $179.50, up 1.87% on the day, with a bullish technical outlook and strong support near $179. The stock shows solid fundamentals with a P/E of 22.11, revenue of $4.70B in 2025, and net income margin of 27.58%. Recent news highlights its position to benefit from data center demand and regulatory support, with an upcoming Q3 earnings call on August 6, 2026.
The outlook is positive with a consensus price target of $191.00, though risks include high capital expenditures and debt levels. Earnings growth and dividend stability provide upside, but investors should monitor execution on capex plans and interest rate impacts.
Incyte (INCY) trades at $114.23, down 2.12% today, with a bullish technical signal supported by moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.81, and revenue growth continues with 2025 revenue at $5.14 billion. Recent developments include positive Phase 1/2 data for VGA039 and the acquisition of Vega Therapeutics, expanding its hematology portfolio.
Outlook remains positive with analyst consensus favoring a Buy rating and a $112.78 price target. Key opportunities include pipeline advancements and robust profitability margins, while risks involve regulatory hurdles and competitive pressures in the biopharmaceutical sector. Earnings growth and product approvals are critical catalysts for future performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Atmos Energy Corporation
Atmos Energy is the largest publicly traded, fully regulated, pure-play natural gas utility in the United States, serving more than 3 million customers in Texas, Colorado, Kansas, Kentucky, Louisiana, Mississippi, Tennessee, and Virginia. About two thirds of its earnings come from Texas, where it distributes natural gas in northern Texas and owns an intrastate gas pipeline spanning several key shale gas formations and interconnected with five storage facilities.
Read more on ATO →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
